[Skip to Content]
[Skip to Content Landing]
Citations 0
October 5, 2005

Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-Metal Stent

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(13):1616-1618. doi:10.1001/jama.294.13.1617-a

To the Editor: Dr Valgimigli and colleagues1 evaluated the clinical and angiographic effects of single high-dose bolus tirofiban plus sirolimus-eluting stenting vs abciximab plus bare-metal stenting. In this study, a baseline Thrombolysis in Myocardial Infarction grade of 0 to 1 was present in more than 70% of patients. A postprocedure grade 3 was achieved in more than 90% of patients, but the myocardial blush grade after reperfusion, one of the most important angiographic indices of myocardial reperfusion and predictors of left ventricular recovery,2 was not mentioned. Also, the authors did not specify if any intracoronary thrombectomy device, balloon predilatation, or intracoronary vasodilators were used.